Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases

Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and...

Full description

Saved in:
Bibliographic Details
Main Authors: Leelawat, Kawin, Narong, Siriluck, Wannaprasert, Jerasak, Leelawat, Surang
Format: Artigo
Language:Inglês
Published: SAGE-Hindawi Access to Research 2011
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170848/
https://ncbi.nlm.nih.gov/pubmed/21994874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4061/2011/873548
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items